Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 36 | 2022 | 2887 | 2.610 |
Why?
|
| Thyroid Neoplasms | 14 | 2021 | 408 | 2.600 |
Why?
|
| Carcinoma, Ductal, Breast | 9 | 2015 | 156 | 1.890 |
Why?
|
| Sentinel Lymph Node Biopsy | 10 | 2018 | 63 | 1.810 |
Why?
|
| Thyroidectomy | 11 | 2021 | 170 | 1.770 |
Why?
|
| Lymph Node Excision | 10 | 2018 | 213 | 1.750 |
Why?
|
| Mastectomy | 17 | 2022 | 236 | 1.730 |
Why?
|
| Lymph Nodes | 12 | 2018 | 530 | 1.710 |
Why?
|
| Carcinoma, Papillary | 8 | 2020 | 158 | 1.540 |
Why?
|
| Carcinoma, Lobular | 8 | 2015 | 80 | 1.530 |
Why?
|
| Mastectomy, Segmental | 7 | 2017 | 92 | 1.530 |
Why?
|
| Adrenocortical Carcinoma | 4 | 2022 | 12 | 1.360 |
Why?
|
| Adrenal Cortex Neoplasms | 4 | 2022 | 18 | 1.360 |
Why?
|
| Iodine Radioisotopes | 6 | 2021 | 134 | 1.350 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2016 | 111 | 1.270 |
Why?
|
| Carcinoma | 4 | 2017 | 436 | 1.000 |
Why?
|
| Parathyroidectomy | 3 | 2020 | 78 | 0.990 |
Why?
|
| Lymphatic Metastasis | 14 | 2020 | 481 | 0.940 |
Why?
|
| Hyperparathyroidism, Primary | 3 | 2020 | 41 | 0.860 |
Why?
|
| Radiopharmaceuticals | 4 | 2016 | 179 | 0.790 |
Why?
|
| Databases, Factual | 13 | 2020 | 812 | 0.750 |
Why?
|
| Axilla | 13 | 2018 | 97 | 0.720 |
Why?
|
| Hypercalcemia | 1 | 2018 | 59 | 0.660 |
Why?
|
| Neoplasm Staging | 16 | 2021 | 1937 | 0.640 |
Why?
|
| Middle Aged | 49 | 2021 | 25017 | 0.630 |
Why?
|
| Thyroid Gland | 6 | 2021 | 270 | 0.600 |
Why?
|
| Female | 57 | 2022 | 44507 | 0.570 |
Why?
|
| Aged | 39 | 2021 | 18402 | 0.560 |
Why?
|
| Humans | 63 | 2022 | 86601 | 0.460 |
Why?
|
| Guideline Adherence | 1 | 2015 | 223 | 0.450 |
Why?
|
| Surgeons | 3 | 2022 | 238 | 0.440 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2021 | 291 | 0.430 |
Why?
|
| Retrospective Studies | 19 | 2022 | 8475 | 0.430 |
Why?
|
| Aged, 80 and over | 16 | 2021 | 6501 | 0.420 |
Why?
|
| Prognosis | 17 | 2019 | 3674 | 0.420 |
Why?
|
| Adult | 31 | 2021 | 25640 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 581 | 0.350 |
Why?
|
| Combined Modality Therapy | 5 | 2022 | 1685 | 0.340 |
Why?
|
| Neck Dissection | 2 | 2021 | 65 | 0.330 |
Why?
|
| Nipples | 5 | 2022 | 36 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2021 | 1313 | 0.310 |
Why?
|
| Logistic Models | 5 | 2020 | 1185 | 0.300 |
Why?
|
| Follow-Up Studies | 14 | 2021 | 3636 | 0.300 |
Why?
|
| United States | 15 | 2022 | 6665 | 0.300 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2019 | 237 | 0.290 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 3 | 2004 | 11 | 0.290 |
Why?
|
| Ergonomics | 3 | 2022 | 21 | 0.280 |
Why?
|
| Neoadjuvant Therapy | 3 | 2017 | 317 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1034 | 0.270 |
Why?
|
| Melanoma | 1 | 2009 | 454 | 0.250 |
Why?
|
| Male | 21 | 2021 | 40956 | 0.240 |
Why?
|
| Survival Rate | 9 | 2020 | 1860 | 0.240 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 541 | 0.240 |
Why?
|
| Patient Selection | 3 | 2013 | 685 | 0.240 |
Why?
|
| Biopsy, Needle | 2 | 2003 | 235 | 0.230 |
Why?
|
| Treatment Outcome | 7 | 2021 | 7988 | 0.220 |
Why?
|
| Brachytherapy | 2 | 2014 | 119 | 0.220 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2022 | 8 | 0.220 |
Why?
|
| Surgical Oncology | 2 | 2020 | 27 | 0.210 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 196 | 0.210 |
Why?
|
| Hospitals, High-Volume | 1 | 2022 | 35 | 0.210 |
Why?
|
| Age Factors | 6 | 2021 | 1849 | 0.200 |
Why?
|
| Risk Factors | 6 | 2021 | 5416 | 0.200 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 645 | 0.200 |
Why?
|
| Breast | 1 | 2003 | 286 | 0.200 |
Why?
|
| Adrenalectomy | 2 | 2018 | 43 | 0.200 |
Why?
|
| Length of Stay | 2 | 2022 | 700 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 864 | 0.190 |
Why?
|
| Mammaplasty | 1 | 2022 | 105 | 0.190 |
Why?
|
| Thyroid Epithelial Cells | 1 | 2020 | 5 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 552 | 0.180 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2020 | 28 | 0.180 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 37 | 0.180 |
Why?
|
| Time Factors | 4 | 2021 | 5209 | 0.170 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 1169 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 860 | 0.160 |
Why?
|
| Thoracic Wall | 1 | 2018 | 21 | 0.160 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2018 | 51 | 0.160 |
Why?
|
| Biopsy | 2 | 2017 | 1161 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2017 | 468 | 0.160 |
Why?
|
| Survival Analysis | 3 | 2016 | 1538 | 0.150 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 387 | 0.150 |
Why?
|
| Radiation Oncology | 1 | 2019 | 119 | 0.150 |
Why?
|
| Prophylactic Mastectomy | 1 | 2016 | 12 | 0.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 108 | 0.140 |
Why?
|
| Neoplasm Grading | 5 | 2016 | 357 | 0.140 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 384 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2020 | 428 | 0.140 |
Why?
|
| Chromatin | 1 | 2018 | 380 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 166 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2019 | 572 | 0.130 |
Why?
|
| Mammography | 3 | 2017 | 461 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 160 | 0.130 |
Why?
|
| Risk | 1 | 2016 | 674 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 479 | 0.120 |
Why?
|
| Prospective Studies | 8 | 2021 | 4210 | 0.120 |
Why?
|
| Young Adult | 6 | 2021 | 5974 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1464 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 97 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 351 | 0.120 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 160 | 0.110 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 192 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1204 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 454 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 252 | 0.110 |
Why?
|
| Thyroid Diseases | 1 | 2013 | 104 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 144 | 0.110 |
Why?
|
| Contraindications | 1 | 2012 | 72 | 0.100 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 173 | 0.100 |
Why?
|
| Workload | 2 | 2022 | 128 | 0.100 |
Why?
|
| Operating Rooms | 2 | 2022 | 126 | 0.100 |
Why?
|
| SEER Program | 3 | 2015 | 184 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 1673 | 0.090 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 45 | 0.090 |
Why?
|
| Propensity Score | 2 | 2021 | 136 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 2436 | 0.080 |
Why?
|
| Radionuclide Imaging | 4 | 2004 | 220 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2009 | 233 | 0.080 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 156 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2009 | 170 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2019 | 839 | 0.080 |
Why?
|
| Adolescent | 5 | 2021 | 8979 | 0.070 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 1074 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 857 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 853 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2006 | 131 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3352 | 0.060 |
Why?
|
| Genome, Human | 1 | 2009 | 756 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2003 | 148 | 0.060 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 468 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2022 | 58 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 2767 | 0.050 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2003 | 99 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2021 | 50 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2022 | 115 | 0.050 |
Why?
|
| Algorithms | 1 | 2009 | 1830 | 0.050 |
Why?
|
| Mass Screening | 1 | 2006 | 617 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 1990 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2020 | 71 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2021 | 288 | 0.050 |
Why?
|
| Herniorrhaphy | 1 | 2020 | 79 | 0.040 |
Why?
|
| Hernia, Inguinal | 1 | 2020 | 67 | 0.040 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2018 | 4 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 93 | 0.040 |
Why?
|
| Reoperation | 1 | 2021 | 597 | 0.040 |
Why?
|
| Conversion to Open Surgery | 1 | 2018 | 11 | 0.040 |
Why?
|
| Thyroid Nodule | 1 | 2018 | 51 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 257 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2018 | 39 | 0.040 |
Why?
|
| Hematoxylin | 1 | 1997 | 6 | 0.040 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 1997 | 10 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 35 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 370 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 999 | 0.040 |
Why?
|
| Keratins | 1 | 1997 | 63 | 0.040 |
Why?
|
| Coloring Agents | 1 | 1997 | 64 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2018 | 332 | 0.040 |
Why?
|
| Ultrasonography, Mammary | 1 | 2017 | 82 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2016 | 81 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2020 | 359 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1239 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 288 | 0.030 |
Why?
|
| Selection Bias | 1 | 2014 | 37 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 301 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2013 | 15 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 642 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2014 | 160 | 0.030 |
Why?
|
| Heterozygote | 1 | 2014 | 365 | 0.030 |
Why?
|
| Age Distribution | 1 | 2013 | 204 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 1997 | 1753 | 0.030 |
Why?
|
| Urban Population | 1 | 2013 | 213 | 0.030 |
Why?
|
| Illinois | 1 | 2013 | 462 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2014 | 326 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2000 | 1074 | 0.030 |
Why?
|
| General Surgery | 1 | 2013 | 228 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 394 | 0.020 |
Why?
|
| Hospitals | 1 | 2013 | 294 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2018 | 754 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2705 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2009 | 35 | 0.020 |
Why?
|
| Postmenopause | 1 | 2009 | 98 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1583 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 2261 | 0.020 |
Why?
|
| Palpation | 1 | 2006 | 18 | 0.020 |
Why?
|
| Community Health Services | 1 | 2006 | 80 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 3967 | 0.010 |
Why?
|
| Ranitidine | 1 | 2000 | 8 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2000 | 90 | 0.010 |
Why?
|
| Premedication | 1 | 2000 | 54 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 299 | 0.010 |
Why?
|
| Physical Examination | 1 | 2000 | 149 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2000 | 295 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 326 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2000 | 556 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 722 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2000 | 460 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2000 | 751 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2000 | 695 | 0.010 |
Why?
|